0000950142-22-003282.txt : 20221130
0000950142-22-003282.hdr.sgml : 20221130
20221130214539
ACCESSION NUMBER: 0000950142-22-003282
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221128
FILED AS OF DATE: 20221130
DATE AS OF CHANGE: 20221130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRY JOHN A
CENTRAL INDEX KEY: 0001255140
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37524
FILM NUMBER: 221437150
MAIL ADDRESS:
STREET 1: C/O DELAWARE INVESTMENTS
STREET 2: 2005 MARKET ST. 34TH FL.
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: vTv Therapeutics Inc.
CENTRAL INDEX KEY: 0001641489
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473916571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3980 PREMIER DR
STREET 2: SUITE 310
CITY: HIGH POINT
STATE: NC
ZIP: 27265
BUSINESS PHONE: 336-841-0300
MAIL ADDRESS:
STREET 1: 3980 PREMIER DR
STREET 2: SUITE 310
CITY: HIGH POINT
STATE: NC
ZIP: 27265
FORMER COMPANY:
FORMER CONFORMED NAME: VTV Therapeutics Inc.
DATE OF NAME CHANGE: 20150506
4
1
es220309096_4-fry.xml
OWNERSHIP DOCUMENT
X0306
4
2022-11-28
0
0001641489
vTv Therapeutics Inc.
VTVT
0001255140
FRY JOHN A
C/O VTV THERAPEUTICS INC.
3980 PREMIER DRIVE, SUITE 310
HIGH POINT
NC
27265
1
0
0
0
Class A common stock
2022-11-28
4
P
0
20539
0.8262
A
20539
D
Class A common stock
2022-11-29
4
P
0
40461
0.8347
A
61000
D
The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.805 to $0.8487, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4.
The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.81 to $0.849, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4.
/s/ Paul Sekhri, as Attorney-in-Fact
2022-11-30